UKSPA Directory 2017 2017-18 - Page 225

UKSPA Directory 2017 England | Full Member 225 Bui l di ngs on si te The Inc ubator Building Ideally suited to start-up biotech companies, this 4,750m 2 building is split between office space (40%) and laboratories (60%). The available space includes hot desks and virtual office facilities, as well as communal facilities, meeting rooms and an atrium. The Ac c ele rator Building and Sanofi within SBC is a glowing endorsement of our model and mantra, as well as recognition of our success in incubating innovation and in developing an Open Innovation ethos across the Campus. They gain access to early stage innovative companies and exciting translational projects in academia. The innovators gain potential access to collaborations and funding – an example of win-win. A key entry criterion for tenancy is that start-ups bring an appetite to engage and collaborate with the corporate players. Small companies that begin in bio- incubators need room to grow. This is the role of the Accelerator. Split between labs and offices, it provides 4,100m 2 of working space for up to 150 people. constantly growing In addition to the Incubator building, the Accelerator building opened in April 2016 and is home to the new MRC Technologies’ National Centre for Therapeutic Drug Discovery. Construction work is continuing on the Campus as we were selected as the site for the £55m state-of-the-art Cell & Gene Therapy Manufacturing Centre, which will open autumn 2017. With long-term plans to expand the campus by fivefold from the first phase to the third phase, Phase 2 of the SBC will provide space for current tenants as they grow, as well as space for new tenants. It is expected that the 25 acre campus will ultimately accommodate 1,500 people. ■ Trans por t l i nks Stevenage rail station 1.5 miles A1(M) Junction 7 Luton and Stansted airports Cell & Ge ne Therapy Manuf acturing Cent re A £55m large scale GMP manufacturing centre for businesses seeking to make products at the later trial stages and for commercialisation. Space will be flexible with users renting appropriate space. N e a r by Str a te g i c n e tw o r k Luton, Hitchin, Welwyn Garden City, Milton Keynes, Cambridge, Watford, Harlow, Chelmsford, London GlaxoSmithKline Wellcome BEIS/Innovate UK